Pravastatin
Active ingredient: Pravastatin Sodium
In short: Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk
What is Pravastatin used for?
Pravastatin sodium tablets are indicated:
To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD).
To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD.
As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
As an adjunct to diet for the treatment of adults with:
Primary dysbetalipoproteinemia.
o Hypertriglyceridemia.
Pravastatin dosage
Take pravastatin sodium tablets orally once daily as a single dose at any time of the day, with or without food.
For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment.
Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pravastatin sodium tablets, and adjust the dosage if necessary.
The recommended starting dosage is pravastatin sodium tablets 40 mg to 80 mg once daily.
In pediatric patients aged 8 to 13 years, the recommended dosage is pravastatin sodium tablets 20 mg once daily.
In pediatric patients aged 14 to 18 years, the recommended starting dosage is pravastatin sodium tablets 40 mg once daily.
In patients with severe renal impairment, the recommended starting dosage is pravastatin sodium 10 mg once daily. Pravastatin sodium tablets are not available in a 10 mg strength. Use another pravastatin sodium product to initiate dosing in such patients. The maximum recommended dosage of pravastatin sodium tablets in patients with severe renal impairment is 40 mg once daily
.
The recommended dosage of pravastatin sodium tablets for patients with mild or moderate renal impairment is the same as patients with normal renal function.
In patients taking a bile acid sequestrant, administer pravastatin sodium tablets at least 1 hour before or 4 hours after the bile acid sequestrant
.
Concomitant use of pravastatin sodium tablets with the following drugs requires dosage modifications of pravastatin sodium tablets
:
Cyclosporine
In patients taking cyclosporine, the recommended starting dosage is pravastatin sodium 10 mg once daily. Pravastatin sodium tablets are not available in a 10 mg strength. Use another pravastatin sodium product to initiate dosing in such patients. The maximum recommended dosage of pravastatin sodium tablets in patients taking cyclosporine is 20 mg once daily.
Clarithromycin and Erythromycin
The maximum recommended dosage is pravastatin sodium tablets 40 mg once daily.
How to take Pravastatin — instructions & advice from the label
Myopathy and Rhabdomyolysis
Advise patients that pravastatin sodium tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever
.
Hepatic Dysfunction
Inform patients that pravastatin sodium tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice
.
Increases in HbA1c and Fasting Serum Glucose Levels
Inform patients that increases in HbA1c and fasting serum glucose levels may occur with pravastatin sodium tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices
.
Pregnancy
Advise pregnant patients and patients who may become pregnant of the potential risk to a fetus. …
Warnings & precautions
Do not take this medicine if: Acute liver failure or decompensated cirrhosis
.
Hypersensitivity to any pravastatin or any excipients in pravastatin sodium tablets.
Pravastatin may cause myopathy and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including pravastatin. Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CK) to greater than 10 times the upper limit of normal (ULN), occurred <0.1% in pravastatin -treated patients in clinical trials.
Risk Factors for Myopathy
Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher pravastatin dosage
.
Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis
Pravastatin is not recommended in patients taking gemfibrozil
.
There are pravastatin dosage restrictions for patients taking cyclosporin and select macrolide antibiotics
.
The following drugs when used concomitantly with pravastatin may also increase the risk of myopathy and rhabdomyolysis: niacin, fibrates, and colchicine
.
Discontinue pravastatin sodium tablets if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Muscle symptoms and CK increases may resolve if pravastatin is discontinued. Temporarily discontinue pravastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis, e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy.
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pravastatin dosage. …
Pravastatin side effects
The following important adverse reactions are described below and elsewhere in the labeling:
Myopathy and Rhabdomyolysis
Immune-Mediated Necrotizing Myopathy
Hepatic Dysfunction
Increases in HbA1c and Fasting Serum Glucose Levels
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In pravastatin placebo-controlled clinical trials, 1313 patients (age range 20 to 76 years, 32% women, 93.5% White, 5% Black, 0.9% Hispanic, 0.4% Asian, 0.2% Other) with a median treatment duration of 14 weeks, 3.3% of patients on pravastatin and 1.2% patients on placebo discontinued due to adverse reactions (regardless of causality). The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: hepatic transaminase elevations, nausea, anxiety/depression, and dizziness. …
Drug interactions
Pravastatin is a substrate of the transport protein OATP1B1. Pravastatin plasma levels can be significantly increased with concomitant administration of inhibitors of OATP1B1. Table 3 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with pravastatin and instructions for preventing or managing them
.
Table 3: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Pravastatin
Gemfibrozil
Clinical Impact: | There is an increased risk of myopathy/rhabdomyolysis when pravastatin is administered with gemfibrozil
Intervention: | Avoid concomitant use of gemfibrozil with pravastatin.
Cyclosporine
Clinical Impact: | The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine with pravastatin.
Intervention: | Initiate with a dosage of pravastatin sodium 10 mg once daily. Pravastatin is not available in a 10 mg strength. Use another pravastatin sodium product to initiate dosing. Do not exceed pravastatin 20 mg once daily
.
Select Macrolide Antibiotics
Clinical Impact: | The risk of myopathy and rhabdomyolysis is increased by concomitant use of clarithromycin or erythromycin with pravastatin. …
About this medicine
Pravastatin sodium, USP is a statin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.
Pravastatin sodium, USP is designated chemically as 1-Naphthalene-heptanoic acid, 1,2,6,7,8,8a-hexahydro-2-methyl-8-(2-methyl-1-oxobutoxy)-β,δ,6-trihydroxy-,monosodium salt, [1S- [1α(βS*,δS*),2α,6α,8β(R*),8aα]]-.
Structural formula:
Pravastatin sodium, USP is white to off-white powder. It is a relatively polar hydrophilic compound with a partition coefficient (n-octanol/water) of 0.59. It is soluble in water (676 mg/mL).
Pravastatin sodium, USP is available for oral administration as 10 mg, 20 mg, 40 mg, and 80 mg tablets. Inactive ingredients include: Croscarmellose sodium, lactose Monohydrate, magnesium oxide, magnesium stearate, microcrystalline cellulose, and povidone.
How it works: Pravastatin is a reversible inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 40aa2d36-57ce-1f48-e063-6294a90affef. Read the full official label on DailyMed.
Related medicines
Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Simvastatin Spironolactone